Mandate

Vinge has advised CELLINK AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised CELLINK AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm Main Market, with an estimated market capitalisation of approximately SEK 4.1 billion. The prospectus was published on 15 April 2020 and the trading on Nasdaq Stockholm commenced on 20 April 2020.

CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. CELLINK focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing. The target is to develop and commercialise cell culture technologies, enabling researchers to 3D-print human organs and tissues for pharmaceutical and cosmetic applications.

Vinge’s team has primarily consisted of Anders Strid, Wibeke Sorling, Edin Agic and Johanna Hamrefält (Capital Markets and Public M&A) as well as Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge advises Lagercrantz Group in connection with the acquisition of ORAX

Lagercrantz Group has acquired all shares in AB ORAX, a leading provider of products for management and maintenance in the funeral and cemetery sector.
June 04, 2025

Vinge has advised Eleda in connection with its acquisition of Rail Solutions Scandinavia AB, Gridtec AB, Quantity Surveying Konsult Stockholm AB, Voene AB, Vägservice centralen i Norden AB and Frästech AB.

Vinge has advised the leading infrastructure group Eleda in connection with its parallel acquisitions of Rail Solutions Scandinavia (railway maintenance), Gridtec (engineering consultancy in electric power), Quantity Surveying Konsult Stockholm (cost control and project management), Voene (traffic safety), Vägservice centralen i Norden and Frästech (road and bridge maintenance). The acquired businesses had a strong profitability with a combined turnover of approximately 200 MSEK in 2024.
June 04, 2025